# Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

> **NCT05791591** · NA · ACTIVE_NOT_RECRUITING · sponsor: **LGD** · enrollment: 168 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DIETARY_SUPPLEMENT:** NUV001 - IR
- **DIETARY_SUPPLEMENT:** NUV001 - GR
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT05791591
- **Lead sponsor:** LGD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-15
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-11-30
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05791591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05791591, "Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05791591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*